US 12,029,581 B2
Systems and methods for assessing the effectiveness of a therapy including a drug regimen using an implantable medical device
Tara L. Crowder, Woodside, CA (US); Brett M. Wingeier, San Francisco, CA (US); Martha J. Morrell, Portola Valley, CA (US); Felice Sun, Palo Alto, CA (US); and Thomas Tcheng, Pleasant Hill, CA (US)
Assigned to NeuroPace, Inc., Mountain View, CA (US)
Filed by NeuroPace, Inc., Mountain View, CA (US)
Filed on Jun. 14, 2021, as Appl. No. 17/346,944.
Application 15/817,160 is a division of application No. 13/539,301, filed on Jun. 30, 2012, abandoned.
Application 17/346,944 is a continuation of application No. 15/817,160, filed on Nov. 17, 2017, granted, now 11,064,926.
Claims priority of provisional application 61/504,164, filed on Jul. 1, 2011.
Prior Publication US 2021/0298654 A1, Sep. 30, 2021
Int. Cl. A61B 5/00 (2006.01); A61B 5/24 (2021.01); A61B 5/377 (2021.01); A61B 5/145 (2006.01); A61B 5/1455 (2006.01)
CPC A61B 5/4848 (2013.01) [A61B 5/0002 (2013.01); A61B 5/0031 (2013.01); A61B 5/24 (2021.01); A61B 5/377 (2021.01); A61B 5/0022 (2013.01); A61B 5/14539 (2013.01); A61B 5/14553 (2013.01); A61B 5/4082 (2013.01); A61B 5/4094 (2013.01)] 17 Claims
OG exemplary drawing
 
17. A method of assessing an effectiveness of an existing drug regimen to which a patient with an implanted medical device is subjected, the method comprising:
delivering, by the implanted medical device, electrical stimulation therapy to the patient's brain according to a set of stimulation parameters;
continuously sensing, by the implanted medical device, electrical activity of the patient's brain;
detecting, by the implanted medical device, epileptiform events in an electrographic signal corresponding to the sensed electrical activity;
detecting, by the implanted medical device, evoked responses in the electrographic signal, and calculating, in response to a detection of an evoked response, a measure of the evoked response;
detecting, by the implanted medical device, a presence of a specified frequency band in the electrographic signal, and calculating, in response to a detection of the specified frequency, a power measure of the electrographic signal in the specified frequency;
logging, by the implanted medical device, information as a function of time, the logged information comprising one or more of a count of occurrences of the epileptiform events, durations of the epileptiform events, measures of the evoked responses, and power measures of the electrographic signal in the specified frequency;
determining, by the implanted medical device, a tracked metric based on changes in the logged information over a time period within which the existing drug regimen, if effective, would affect the tracked metric;
determining, by the implanted medical device, the existing drug regimen is not effective responsive to the tracked metric not satisfying a criterion relative to a corresponding baseline metric; and
responsive to determining that the existing drug regimen is not effective, adjusting, by the implanted medical device, the set of stimulation parameters based on a mechanism of action of a drug of the existing drug regimen.